Please Wait
Applying Filters...
menu
    • menu
    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    Evonik

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-04-28

    Virtual Booth

    An Enquiry

    Menu

    Avutometinib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Verastem Announces KRAS Ovarian Cancer Launch, Debt Refinancing
    Verastem Announces KRAS Ovarian Cancer Launch, Debt Refinancing

    13 Jan 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250113992572/en

    BUSINESSWIRE
    13 Jan 2025
    Share Share
    Verastem Announces FDA Acceptance for Avutometinib in Ovarian Cancer
    Verastem Announces FDA Acceptance for Avutometinib in Ovarian Cancer

    30 Dec 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241230294719/en

    BUSINESSWIRE
    30 Dec 2024
    Share Share
    Verastem Complete NDA Submission for Avutometinib in Ovarian Cancer
    Verastem Complete NDA Submission for Avutometinib in Ovarian Cancer

    31 Oct 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241031747822/en

    BUSINESSWIRE
    31 Oct 2024
    Share Share
    Verastem Announces RAMP 201 Data Oral Presentation At IGCS 2024
    Verastem Announces RAMP 201 Data Oral Presentation At IGCS 2024

    09 Oct 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241009704485/en

    BUSINESSWIRE
    09 Oct 2024
    Share Share
    Verastem Receives FDA Orphan Drug Designation For Pancreatic Cancer
    Verastem Receives FDA Orphan Drug Designation For Pancreatic Cancer

    29 Jul 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240729473398/en

    BUSINESSWIRE
    29 Jul 2024
    Share Share
    ASCO: Verastem’s combo therapy for pancreatic cancer hits early trial success
    ASCO: Verastem’s combo therapy for pancreatic cancer hits early trial success

    25 May 2024

    // Robert Barrie CLINICALTRIALSARENA

    https://www.clinicaltrialsarena.com/news/asco-2024-verastems-combo-therapy-for-pancreatic-cancer-hits-early-trial-success/#:~:text=clinical%20research%20companies-,ASCO%202024%3A%20Verastem\'s%20combo%20therapy%20for%20pancreatic%20cancer%20hits%20early,%25%20in%20pre%2Dmarket%20trading.&text=Verastem%20will%20present%20the%20results,Meeting%20on%201%20June%202024.

    Robert Barrie CLINICALTRIALSARENA
    25 May 2024
    Share Share